UPDATE ON THALASSEMIA TREATMENT IN TAIWAN, INCLUDING BONE MARROW TRANSPLANTATION, CHELATION THERAPY, AND CARDIOMYOPATHY TREATMENT EFFECTS

作者：Peng Ching Tien; Chang Jeng Sheng; Wang Lin Yen; Chiou Shyh Shin; Hsiao Chih Cheng; Wang Shih Chung; Hung Giun Yi; Wu Kang Hsi^*

来源：Hemoglobin, 2009, 33(5): 304-311.

DOI：10.1080/03630260903212969

Over the past few decades, Taiwan has seen striking improvements in the life expectancy of its 400 registered beta-thalassemia major (beta-TM) patients due mainly to adequate transfusion regimens and effective iron chelation therapy. Since 1995, Taiwanese citizens have enjoyed universal health care through National Health Insurance (NIH), receiving comprehensive treatment at minimal cost. In 1984, a national program for thalassemia prevention, control, and hematopoietic stem cell transplantation (HSCT) was initiated. Recent data show 1- and 2-year event-free survival rates of 85 and 78%, respectively. Chelation agents like deferoxamine (DFO), deferiprone (L1) and deferasirox (DFRA) are available in Taiwan, and therapy is tailored to individuals based on drug availability and tissue distribution of iron load. Intensive chelation regimens combining L1 and DFO are recommended in patients with cardiac complications, while DFRA has been found to be effective in reducing serum ferritin, with acceptable side effects. Here, we report advances in thalassemia treatment in Taiwan and suggest treatment guidelines.

• 出版日期2009
• 单位中国医科大学